🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524543-12-00
Authorised Phase II

The efficacy of oral vancomycin therapy in managing different phenotypes of paediatric inflammatory bowel diseases by correlating treatment response to commensal microbiota composition and function (VERDA)

2025-524543-12-00 · tracked via the Priya Life Science EU tracker
Sponsor
Pirkanmaan hyvinvointialue
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Digestive System Diseases
Decision date
24/03/2026
Enrollment target
140
Sites
Finland

Condition studied

Ulcerative colitis

Investigational medicinal product(s)

Vancomycin Xellia 250 mgkapselikovaVancomycin Xellia 125 mgkapselikova

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

Suolen tervehtyminen (remissio eli lapsi on oireeton ja ulosteen kalprotektiini on alle 100), Miltä suolen bakteeristo näyttää ennen vankomysiinihoitoa tai tavanomaista hoitoa tulehduksen aikana ja remissiossa hoidon aloittamisen jälkeen

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524543-12-00 on CTIS ↗ ← All trials in the EU